@article{104aabdf7638454f97957b3198e1ede5,
title = "Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy",
abstract = "Helper (CD4+) T cells perform direct therapeutic functions and augment responses of cells such as cytotoxic (CD8+) T cells against a wide variety of diseases and pathogens. Nevertheless, inefficient synthetic technologies for expansion of antigen-specific CD4+ T cells hinders consistency and scalability of CD4+ T cell-based therapies, and complicates mechanistic studies. Here we describe a nanoparticle platform for ex vivo CD4+ T cell culture that mimics antigen presenting cells (APC) through display of major histocompatibility class II (MHC II) molecules. When combined with soluble co-stimulation signals, MHC II artificial APCs (aAPCs) expand cognate murine CD4+ T cells, including rare endogenous subsets, to induce potent effector functions in vitro and in vivo. Moreover, MHC II aAPCs provide help signals that enhance antitumor function of aAPC-activated CD8+ T cells in a mouse tumor model. Lastly, human leukocyte antigen class II-based aAPCs expand rare subsets of functional, antigen-specific human CD4+ T cells. Overall, MHC II aAPCs provide a promising approach for harnessing targeted CD4+ T cell responses.",
author = "Ariel Isser and Silver, {Aliyah B.} and Pruitt, {Hawley C.} and Michal Mass and Elias, {Emma H.} and Gohta Aihara and Kang, {Si Sim} and Niklas Bachmann and Chen, {Ying Yu} and Leonard, {Elissa K.} and Bieler, {Joan G.} and Worarat Chaisawangwong and Joseph Choy and Shannon, {Sydney R.} and Sharon Gerecht and Weber, {Jeffrey S.} and Spangler, {Jamie B.} and Schneck, {Jonathan P.}",
note = "Funding Information: This work was supported by National Institutes of Health (NIH) Grants R01EB029341 (J.P.S.), R33CA229042 (J.P.S.), P41EB028239 (J.P.S.), R01EB029341 (J.B.S), R21CA249381 (J.B.S.), R01EB029455 (J.B.S), and U54CA210173 (S.G.), Department of Defense grant W81XWH21P0031 (J.B.S.), a Sponsored Research Agreement with NexImmune (J.P.S.), Maryland Stem Cell Research Fund grant 2019-MSCRFD-5039 (J.B.S.), a V Foundation Scholars award V2018-005 (J.B.S.), and an Emerson Collective Cancer Research Fund award (J.B.S.). A.I. is supported by the National Science Foundation (NSF) Graduate Research Fellowship 2016218370 and the NIH National Research Service Award graduate fellowship F31CA254121. A.B.S. is supported by the NIH Training Grant T32AI007417. H.C.P. is supported by the NIH Training Grant T32CA153952-09. S.-S.K. is supported by the Scholarship for Doctoral Programs Overseas, Ministry of Education, Taiwan. E.K.L. is supported by the NIH Training Grant K12GM12391401A1. J.C. the support of the Natural Sciences and Engineering Research Council of Canada award PGSD3-557758-2021. We thank the NIH Tetramer Core Facility for providing I-AbOVA329-337 , I-AbCLIP87-101 , and I-AbLCMV GP66-77 biotinylated monomers and PE-labeled tetramers. We thank the Johns Hopkins Immunogenetics Core for providing HLA DR4 Lymphoblastoid Cell Lines (LCL). We thank Sheila Drover for the HLA DR4-restricted NFLD.D.1 hybridoma supernatant. Lastly, we thank Luc Teyton for the HLA-DR1 Plasmids. Schematics were prepared with permission using BioRender software. Funding Information: This work was supported by National Institutes of Health (NIH) Grants R01EB029341 (J.P.S.), R33CA229042 (J.P.S.), P41EB028239 (J.P.S.), R01EB029341 (J.B.S), R21CA249381 (J.B.S.), R01EB029455 (J.B.S), and U54CA210173 (S.G.), Department of Defense grant W81XWH21P0031 (J.B.S.), a Sponsored Research Agreement with NexImmune (J.P.S.), Maryland Stem Cell Research Fund grant 2019-MSCRFD-5039 (J.B.S.), a V Foundation Scholars award V2018-005 (J.B.S.), and an Emerson Collective Cancer Research Fund award (J.B.S.). A.I. is supported by the National Science Foundation (NSF) Graduate Research Fellowship 2016218370 and the NIH National Research Service Award graduate fellowship F31CA254121. A.B.S. is supported by the NIH Training Grant T32AI007417. H.C.P. is supported by the NIH Training Grant T32CA153952-09. S.-S.K. is supported by the Scholarship for Doctoral Programs Overseas, Ministry of Education, Taiwan. E.K.L. is supported by the NIH Training Grant K12GM12391401A1. J.C. the support of the Natural Sciences and Engineering Research Council of Canada award PGSD3-557758-2021. We thank the NIH Tetramer Core Facility for providing I-A OVA, I-A CLIP, and I-A LCMV GP biotinylated monomers and PE-labeled tetramers. We thank the Johns Hopkins Immunogenetics Core for providing HLA DR4 Lymphoblastoid Cell Lines (LCL). We thank Sheila Drover for the HLA DR4-restricted NFLD.D.1 hybridoma supernatant. Lastly, we thank Luc Teyton for the HLA-DR1 Plasmids. Schematics were prepared with permission using BioRender software. b 329-337 b 87-101 b 66-77 Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41467-022-33597-y",
language = "English (US)",
volume = "13",
journal = "Nature communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}